You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Multi-Functional Nanotube-Based Sensor Array for Detecting Blood Coagulation Defects

    SBC: Innosense Llc            Topic: DHA19A001

    Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). Blood coagulopathy, resulting in uncontrolled bleeding, is implicated in 80% of operating room deaths and 50% of trau

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  2. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  4. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: Luna Innovations Incorporated            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  5. Smart Baseplate for Additive Manufacturing

    SBC: Luna Innovations Incorporated            Topic: DLA18A001

    Additive manufacturing (AM) has rapidly evolved into a valuable technique for making parts which, at times, cannot be fabricated through conventional machining methods.One challenge in the area of AM is the lack of real-time feedback on the fabrication process and the quality of the part being made.This is especially critical given the relatively long periods of time that complex parts can require ...

    STTR Phase I 2018 Department of DefenseDefense Logistics Agency
  6. Additive Manufacturing Sensor Fusion Technologies for Process Monitoring and Control.

    SBC: SENVOL LLC            Topic: DLA18A001

    The Department of Defense (DoD) has a demand for out-of-production parts to maintain mission readiness of various weapons platforms. Additive manufacturing (AM) is an exciting and promising manufacturing technique that can make out-of-production parts and holds the potential to solve supply chain issues, such as high costs (i.e. for low-volume parts) and sole sourcing risks. The ability of AM to s ...

    STTR Phase I 2018 Department of DefenseDefense Logistics Agency
  7. Functionalized, Therapeutic-Loaded Liposomes for the Acute Treatment of TBI

    SBC: Luna Innovations Incorporated            Topic: DHA18A001

    Traumatic brain injury is a common problem in both the military and civilian communities, but current treatment protocols are focused on managing symptoms and fail to prevent significant long-term repercussions. In the proposed program, Luna will demonstrate the feasibility of a liposome-based therapeutic delivery system capable of delivering hydrophilic and hydrophobic therapeutics to the traumat ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  8. Human Performance Optimization: Ketone Esters for Optimization of Operator Performance in Hypoxia

    SBC: HVMN Inc.            Topic: SOCOM17C001

    In the setting of altitude-induced hypoxia, operator cognitive capacity degrades and can compromise both individual and team performance. This degradation is linked to falling brain energy (ATP) levels and an increased reliance on anaerobic energy production from glucose. Ketone bodies are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies have sho ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  9. Inhibiting Prolyl Hydroxylase to Mimic Natural Acclimatization to High Altitude to Improve Warfighter Performance at High Altitude

    SBC: Research Logistics Company            Topic: SOCOM17C001

    Acclimatization is the long-term adjustment that humans experience when exposed for weeks or months to high altitude. Acclimatization is important in this context because a warfighter who is acclimatized to high altitude is immune to high altitude illness, has superior work capacity, and has cognitive function approaching that found at sea level. In other words, the acclimatized warfighter is opti ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  10. Probabilistic Pharmacokinetic Models for Diagnosis, Prognosis, and Personalized Treatment

    SBC: BARRON ASSOCIATES, INC.            Topic: DHA17B003

    Clinicians have recognized that the nature of diseases can be highly individual resulting in different patterns of onset and progression. In turn, the response of an individual to drugs is also unique and governed by a variety of factors. Pharmacokinetic models represent the movement of a drug through the body, and personalized pharmacokinetic models aim to capture the unique responses of specific ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government